Merck & Co., Inc. (MRK) Shares Bought by Nomura Asset Management Co. Ltd.

Nomura Asset Management Co. Ltd. grew its position in Merck & Co., Inc. (NYSE:MRK) by 0.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,243,081 shares of the company’s stock after purchasing an additional 1,994 shares during the period. Merck & Co., Inc. comprises about 0.8% of Nomura Asset Management Co. Ltd.’s holdings, making the stock its 24th largest position. Nomura Asset Management Co. Ltd.’s holdings in Merck & Co., Inc. were worth $75,455,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of MRK. Cobblestone Capital Advisors LLC NY increased its holdings in shares of Merck & Co., Inc. by 0.4% during the 2nd quarter. Cobblestone Capital Advisors LLC NY now owns 187,080 shares of the company’s stock valued at $11,356,000 after acquiring an additional 774 shares during the last quarter. Mckinley Capital Management LLC Delaware increased its holdings in shares of Merck & Co., Inc. by 5.6% during the 2nd quarter. Mckinley Capital Management LLC Delaware now owns 15,447 shares of the company’s stock valued at $938,000 after acquiring an additional 815 shares during the last quarter. Summit X LLC increased its holdings in shares of Merck & Co., Inc. by 9.2% during the 1st quarter. Summit X LLC now owns 10,093 shares of the company’s stock valued at $552,000 after acquiring an additional 850 shares during the last quarter. Covenant Asset Management LLC increased its holdings in shares of Merck & Co., Inc. by 1.4% during the 2nd quarter. Covenant Asset Management LLC now owns 62,353 shares of the company’s stock valued at $3,785,000 after acquiring an additional 850 shares during the last quarter. Finally, First Midwest Bank Trust Division increased its holdings in shares of Merck & Co., Inc. by 2.1% during the 2nd quarter. First Midwest Bank Trust Division now owns 42,242 shares of the company’s stock valued at $2,564,000 after acquiring an additional 869 shares during the last quarter. 72.19% of the stock is currently owned by institutional investors.

Shares of MRK stock opened at $70.83 on Friday. The company has a quick ratio of 1.04, a current ratio of 1.33 and a debt-to-equity ratio of 0.61. Merck & Co., Inc. has a 12 month low of $52.83 and a 12 month high of $70.94. The company has a market capitalization of $188.36 billion, a price-to-earnings ratio of 17.80, a PEG ratio of 2.41 and a beta of 0.81.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Friday, July 27th. The company reported $1.06 EPS for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.03. Merck & Co., Inc. had a return on equity of 32.68% and a net margin of 3.67%. The company had revenue of $10.47 billion during the quarter, compared to the consensus estimate of $10.28 billion. During the same quarter last year, the company earned $1.01 EPS. The company’s quarterly revenue was up 5.4% on a year-over-year basis. equities research analysts forecast that Merck & Co., Inc. will post 4.27 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 5th. Shareholders of record on Monday, September 17th will be given a $0.48 dividend. The ex-dividend date is Friday, September 14th. This represents a $1.92 dividend on an annualized basis and a dividend yield of 2.71%. Merck & Co., Inc.’s dividend payout ratio is currently 48.24%.

In other Merck & Co., Inc. news, VP Rita A. Karachun sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 2nd. The stock was sold at an average price of $65.01, for a total value of $325,050.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Sanat Chattopadhyay sold 29,208 shares of the firm’s stock in a transaction that occurred on Friday, August 3rd. The stock was sold at an average price of $65.20, for a total value of $1,904,361.60. Following the completion of the sale, the insider now owns 70,675 shares of the company’s stock, valued at approximately $4,608,010. The disclosure for this sale can be found here. Insiders sold a total of 396,393 shares of company stock valued at $25,235,061 in the last quarter. Corporate insiders own 0.32% of the company’s stock.

A number of research analysts have recently commented on MRK shares. Zacks Investment Research raised Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $69.00 price objective on the stock in a report on Thursday, June 7th. TheStreet raised Merck & Co., Inc. from a “c+” rating to a “b-” rating in a report on Friday, June 8th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $59.00 target price on shares of Merck & Co., Inc. in a report on Sunday, July 15th. BMO Capital Markets reaffirmed a “buy” rating and issued a $70.00 target price on shares of Merck & Co., Inc. in a report on Sunday, July 22nd. Finally, Bank of America raised their target price on Merck & Co., Inc. from $70.00 to $74.00 and gave the company a “buy” rating in a report on Monday, July 30th. Six equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $67.93.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Featured Article: Intrinsic Value and Stock Selection

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply